Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses HAP Data, Informatics to AstraZeneca

NEW YORK, Dec. 11 - Genaissance Pharmaceuticals has given AstraZeneca access to specific HAP markers and its DecoGen informatics platform to help the pharmaceutical firm bolster its drug-discovery efforts, Genaissance said on Tuesday.


Financial or research details of the deal, the third of its kind that Genaissance has struck with a major pharmaceutical company, were not disclosed.


Genaissance, of New Haven, Conn., has a cache of almost 100,000 haplotypes from more than 5,400 genes and said it intends to discover haplotypes for all human genes.


"Pharmacogenomics has an expanding role to play in drug discovery and development," John Stageman, AstraZeneca's vice president of enabling science and technology, said in a statement. "AstraZeneca looks forward to using Genaissance's advanced HAP Technology platform and evaluating its potential to accelerate our internal efforts."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.